What this is
- This research focuses on enhancing the delivery of mRNA using PEGylated lipo-xenopeptide carriers.
- The study investigates how improves the colloidal stability of these carriers and facilitates targeted delivery to specific cells.
- It also addresses the balance between achieving effective transfection efficiency while minimizing nonspecific interactions.
Essence
- of lipo-xenopeptide carriers enhances their stability and targeting capabilities for mRNA delivery, but higher PEG ratios may reduce transfection efficiency.
Key takeaways
- improved the colloidal stability of LAF-XP polyplexes, enabling them to resist aggregation from salts and proteins.
- Higher PEG ratios (10% and 20%) effectively shielded the carriers but decreased transfection efficiency, a known challenge in mRNA delivery.
- Functionalization with the EGFR-targeting ligand GE11 restored transfection efficiency in EGFR-positive cell lines, demonstrating the potential for targeted mRNA delivery.
Caveats
- Higher PEG ratios can lead to reduced transfection efficiency, complicating the balance between stability and efficacy.
- The study primarily focuses on in vitro results; in vivo performance may vary and requires further investigation.
Definitions
- PEGylation: The process of attaching polyethylene glycol (PEG) chains to molecules, enhancing their stability and reducing immunogenicity.
Simplified
1. Introduction
Therapeutic nucleic acids, such as mRNA, hold great potential for the prevention and treatment of diseases such as cancer and genetic disorders. However, due to their large size and negative charge, nucleic acids are unable to cross the lipid bilayer of cells efficiently. To facilitate this process, a delivery system is required. Viral vectors have proven to be highly effective for this purpose, and the majority of clinical trials rely on them. Their application is limited by restricted cargo capacity, immunogenicity, and challenges in large-scale production [1,2]. Non-viral vectors represent promising alternatives if their efficiencies can be improved. Various carrier systems [3,4,5,6,7,8] have been developed such as lipoplexes [9,10], polyplexes [11,12,13,14,15,16,17], and lipid nanoparticles (LNPs) [18,19]. Among these, LNPs have emerged as the current state-of-the-art delivery system. For instance, Onpattro, an LNP formulation, was the first FDA approved siRNA drug for the treatment of hereditary transthyretin amyloidosis [20]. This was followed by the widely recognized COVID-19 vaccines, Spikevax (Moderna) and Comirnaty (BioNTech) [21,22], both LNP formulations, and also encouraging clinical studies with Cas9 mRNA LNP drug Nexiguran Ziclumeran [23]. LNPs exhibit excellent transfection efficiencies and offer good colloidal stability. However, their formulation process is complex. Typically, they are made of a four-component system containing a helper lipid, cholesterol, a polyethylene glycol (PEG)-conjugated lipid, and an ionizable lipid. While the ionizable lipid complexes nucleic acid and mainly drives transfection, helper lipids are required to generate optimal function. The lipids are soluble only in organic solvents, such as ethanol, while the nucleic acids are dissolved in acidic aqueous buffers. After LNP preparation, the particles must be diluted and dialyzed to remove the organic solvent and adjust the pH to a physiological level.
In contrast, polyplexes and lipoplexes have the advantage of a simple formulation process. Nucleic acid and cationic carrier are mixed in an aqueous buffer, for which there is no need for subsequent dilution or dialysis. Compared to standard four-component LNPs, plain cationic polyplexes and lipoplexes encounter greater challenges in maintaining colloidal stability, making them more prone to aggregation in the presence of salts, proteins, and serum, which can substantially influence their biosafety [16,24]. Furthermore, their higher positive surface charge increases recognition by the innate immune system via complement activation, which potentially triggers inflammation [25,26,27]. Surface modification of nanoparticles with hydrophilic, flexible polymers provided "stealth" properties, i.e., dramatically enhanced colloidal stability and blood circulation times [28]. Shielding polymers such as PEG [29,30,31,32,33,34,35,36,37,38], pHPMA [39,40], poly(2-oxazoline) (pOx) [41,42], and polysarcosine [43,44,45] have been incorporated also into lipoplexes and polyplexes, greatly improving stability and reducing serum–protein interactions of these nucleic acid complexes.
Lipid-conjugated PEG is the key component for maintaining colloidal stability of LNPs [46,47,48,49]. Historically, PEG lipids were first introduced into liposomes and cationic lipid/DNA complexes (lipoplexes) [28,29,50,51,52,53,54,55,56,57]. Two commonly used PEG lipids are DMG-PEG and DSPE-PEG-N3, often applied with a 2 kDa average molecular weight of PEG. Both PEG lipids consist of a hydrophilic PEG polymer linked to a lipid anchor. DMG-PEG contains a shorter anchor composed of two C14 myristic acid chains, whereas DSPE-PEG-N3 features longer C18 stearic acid chains. The shorter lipid anchor of DMG-PEG results in weaker incorporation within the LNP helper lipid surface, which makes it more prone to dissociation ("sheddable PEG"). In the case of the siRNA drug Onpattro and related LNPs, DMG-PEG ensures colloidal stability during formulation and upon intravenous administration, where it detaches from the LNP within the blood stream [58]. This enables apolipoprotein E (apoE) adsorption, which facilitates delivery to hepatocytes. In contrast, PEG lipids with longer hydrocarbon chains, such as DSPE-PEG, are more strongly anchored within the LNP and dissociate more slowly, resulting in longer circulation time [59,60,61,62,63]. Due to this firm anchoring, DSPE-PEG derivatives are also commonly used for cell-specific delivery. The PEG lipids thereby can be functionalized via a reactive terminal linker with a targeting moiety. This enables LNPs to achieve specific delivery via ligand–receptor interactions. Numerous studies demonstrated this approach [64,65,66,67,68,69,70].
Our lab has recently developed double-pH-responsive lipo-amino fatty acid (LAF)-modified xenopeptide carriers (LAF-XPs) that undergo a lipophilic-to-hydrophilic polarity switch upon endosomal protonation [71,72]. LAF-XPs can be synthesized in a precise sequence-controlled manner using fmoc-based solid-phase-assisted peptide synthesis (SPPS). In this process, the polar artificial poly-amino acid succinoyl tetraethylene pentamine (Stp), introduced in properly tBoc protected form, is combined with apolar LAF units via bridging lysine units (Scheme 1a) in various different sequences, ratios, and topologies (Scheme 1b). Formulations with this novel carrier class present a sweet spot between cationic lipoplexes and polyplexes. The carriers share a certain similarity with classical cationic lipids used to form lipoplexes, but instead of a small polar head group they comprise a far larger ionizable polycationic polar domain. With 8 to >10 protonatable nitrogens, they are significantly smaller then commonly applied cationic polymers but display sufficient cationic charges and aqueous solubility to be employed for polyplex formulation [71]. With increased content of LAF units, they also can be used as ionizable lipids to formulate novel LNPs with exceptionally effective endosomal escape properties [73,74]. Formulation of LAF-XP carriers with RNA either as complexes or (in combination with helper lipids and cholesterol) as LNPs has shown exceptional transfection efficiency in vitro and in vivo [71,72,73,74].
The current study aims for the development of LAF-XP mRNA polyplex formulations with increased colloidal stability, offering the potential for shielding against inadvertent unspecific biological interactions and the option for specific cell-receptor-targeted delivery. Noncovalent hydrophobic incorporation of PEG lipid DMG-PEG (for colloidal stabilization and shielding) or DSPE-PEG-N3 (for click-chemistry-based ligand incorporation) into mRNA complexes was considered as fast and feasible strategy. In previously explored lipoplexes and LNPs, PEG lipids are rather stably anchored in the outer lipid shell of the LNP primarily via hydrophobic interactions with helper phospholipids (e.g., DSPC and cholesterol) [75,76]. For the current work we hypothesized that under neutral physiological conditions, the PEG lipids can be successfully anchored within the hydrophobic domain of LAF-XP mRNA complexes but would be released from polyplexes with endosomal protonation of lipidic LAF domains, thus recovering full endosomolytic release capacity.
2. Materials and Methods
2.1. Materials
Chemically modified CleanCap® FLuc mRNA (5moU) was acquired from Trilink Biotechnologies (San Diego, CA, USA). EZ Cap™ Cy5 Firefly luciferase mRNA (5-moUTP) was bought from Apexbio Technology LLC (Houston, TX, USA). Plasmid pCMVLuc (encoding Photinus pyralis firefly luciferase regulated with a cytomegalovirus promoter and enhancer) was obtained from Plasmid Factory GmbH (Bielefeld, Germany). 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carbonyl-azido(polyethylene glycol)-2000] (DSPE-PEG-N3) were bought from Avanti Polar Lipids (Alabaster, AL, USA). Agarose BioReagent low EEO, boric acid, bromophenol blue, ethidium bromide (EtBr) (1% solution in H2O), glycerol, RNase-free water, tris(hydroxymethyl) aminomethane hydrochloride (Tris-HCl), and triton X-100 were procured from Sigma-Aldrich (Munich, Germany); 4-(2-hydroxyethyl) 1-piperazineethanesulfonic acid (HEPES) from Biomol (Hamburg, Germany); GelRed (1000×) from VWR (Darmstadt, Germany); and D-(+)-glucose monohydrate, Silver Nitrate (AgNO3), disodium carbonate (Na2CO3), sodium thiosulfate (Na2S2O3), and ethylene diaminetetraacetic acid (EDTA) from Merck (Darmstadt, Germany). The Quant-iT™ RiboGreen RNA Assay Kit was purchased from Thermo Fisher Scientific (Schwerte, Germany) and heparin (5000 I.U. mL−1) from B. Braun SE (Melsungen, Germany). All cell culture consumables were purchased from Faust Lab Science (Klettgau, Germany). N2a cells (murine neuroblastoma cell line Neuro2a) and HepG2 cells (human hepatocellular carcinoma) were from the American Type Culture Collection (ATCC, Manassas, VA, USA) and human adherent hepatic carcinoma Huh7 wild-type cell lines from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). The human cervical cancer KB cell line was purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ; Braunschweig, Germany). Low-glucose Dulbecco's modified Eagle's medium (DMEM), DMEM Ham's F12 medium, fetal bovine serum (FBS), penicillin (100 U mL−1) and streptomycin (100 µg mL−1), trypsin/EDTA, as well as paraformaldehyde (PFA) were bought from Sigma-Aldrich (Munich, Germany) and PAN-Biotech (Aidenbach, Germany). The 5× cell culture lysis buffer and D-luciferin sodium salt were acquired from Promega (Mannheim, Germany. β-mercaptoethanol, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyiltetrazolium bromide (MTT), 4′,6-diamidino-2-phenylindole (DAPI), dithiothreitol (DTT), adenosine 5′-triphosphate (ATP) disodium salt trihydrate, coenzyme A trilithium salt, glycylglycine, magnesium chloride (MgCl2), and 2,5-DHB and 2-hydroxy-5-methoxybenzoic acid (super-DHB) were acquired from Sigma-Aldrich (Munich, Germany). Polypropylene syringe microreactors were obtained from Multisyntech (Witten, Germany). Trifluoroacetic acid (99%, extra pure) (TFA), sodium hydroxide (1M NaOH), dichloromethane, HPLC reagent grade (DCM), acetonitrile, HPLC reagent grade (ACN), N,N-dimethylformamide (99.8%, extra dry over molecular sieve), croSeal (dry DMF), and acetic acid (CH3COOH) were purchased from Thermo Fisher Scientific GmbH (Schwerte, Germany). Sodium dodecyl sulfate (SDS) was purchased from SERVA Electrophoressis GmbH (Heidelberg, Germany). Formaldehyde (CH2O) was bought from Grüssig GmbH (Flisum, Germany). Fmoc-protected amino acids; 2-chlorotritylchloride polystyrene resin; dimethylformamide; N-methyl-2-pyrrolidone (NMP); DBCO-NHS; O-(benzotriazol-1-yl)-N; N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU); and piperidine were acquired from Iris Biotech (Marktredwitz, Germany). Diisopropylethylamine (DIPEA), 1-hydroxybenzotriazole hydrate (HOBt), methanol (CH3OH), bromophenol blue, and triisopropylsilane (TIS) were purchased from Sigma-Aldrich (Munich, Germany). (Benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PyBOP) was procured from Millipore (Oakville, Canada). Trifluoroacetic acid was obtained from Acros Organics (Geel, Belgium). Linear polyethylenimine (LPEI) 22 kDa was synthesized according to a previously published procedure [77].
2.2. Methods
2.2.1. Synthesis of LAF-XP Carriers
The ionizable LAF-Stp carriers were synthesized using solid-phase peptide synthesis (SPPS) according to the protocol reported by Thalmayr et al. [71].
2.2.2. Copper-Free Click Reaction for DSPE-PEG-GE11 Conjugate Formation
Equimolar amounts of DSPE-PEG-N3 and DBCO-GE11/DBCO-GE11scr peptide were mixed and incubated in HBG overnight on a shaker at 25 °C and 250 rpm.
2.2.3. Unmodified and PEGylated LAF-XP Polyplex Formation
The nucleic acid was first diluted in HBG (20 mm of HEPES, 5% (w/v) glucose, pH 7.4). Separately, the LAF-XP carrier at the specified N/P ratios, along with the selected PEG lipid at defined molar ratios, was diluted in Milli-Q water. For calculating the N/P ratio, all secondary amines within the Stp (succinoyl tetraethylene pentamine) units, the amine groups, and the tertiary amines of the LAFs were taken into account. Equal volumes of nucleic acid solution and LAF carrier/PEG lipid solution were mixed by rapid pipetting and incubated for 40 min at RT in a closed Eppendorf reaction tube. The final concentration of nucleic acid in the LAF-XP polyplex solution was 12.5 μg/mL for mRNA and 10 μg/mL for pDNA, if not otherwise stated. Each carrier was formulated at its respective optimal nitrogen-to-phosphate ratios (N/P): for mRNA, bundles 1621 and 1752 at N/P 24, 1611 at N/P 18, and 1719 at N/P 12, and for pDNA, 1719 and 1730 at a N/P ratio of 12 and 1611 at a N/P ratio of 18.
2.2.4. Zetasizer Measurements
Measurements were carried out using a Zetasizer Nano ZS (Malvern Instruments, Malvern, Worcestershire, UK) using a folded capillary cell (DTS1070) by dynamic and electrophoretic laser light scattering (DLS, ELS). To assess the particle size and polydispersity index (PDI), 40 µL LAF polyplex solutions were prepared as described above (), diluted with 40 µL HBG, and analyzed with the following settings: 30 s of equilibration time, temperature 25 °C, refractive index 1.330, and viscosity 0.8872 mPa*s. Each sample was measured three times with six sub-runs per measurement. To determine the zeta potential, the polyplex solution was diluted with 720 µL of HBG and thoroughly mixed by pipetting prior to measurement. Measurement settings were identical to size determination, with the exception of an increase in equilibration time of 60 s. Each sample was measured with 15 sub-runs (10 s each), and zeta potential was calculated by the Smoluchowski equation. All results (size, PDI, and zeta potential) were reported as mean ± SD out of these measurements. Section 2.2.3
2.2.5. Cell Culture
The human adherent hepatic carcinoma cell lines Huh7 and HepG2 were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with F12 Ham. KB and N2a (murine adherent neuroblastoma cell line Neuro2a) were cultivated in low-glucose DMEM (1 g/L glucose). All cell culture media were supplemented with 100 U/mL penicillin, 10% fetal bovine serum (FBS), 4 mM of stable glutamine, and 100 µg/mL streptomycin.
2.2.6. Transfections
LAF polyplexes were prepared as described above (Section 2.2.3) for transfections. Cells were seeded 24 h prior to the transfection. For Huh7, 8000 cells/well; for KB, 5000 cells/well; and for N2a and HepG2 cells, 10,000 cells/well were seeded on a 96-well plate. The medium was replaced with fresh medium before transfection. For mRNA, the volumes of 2.0 and 1.25 μL of LAF polyplex solution (12.5 μg/mL mRNA-luc) were added to the corresponding wells in triplicate. In the case of pDNA, 5.0 μL of LAF polyplex solution (10 μg/mL) was added to each well. HBG/H2O (50/50) was used as a negative control.
2.2.7. Luciferase Gene Expression Assay
Transfections of LAF polyplexes were carried out as described (Section 2.2.6). After 24 h incubation time, the medium was removed. Next, 100 µL of 0.5× lysis buffer was added to each well, and the cells were stored and frozen overnight at −80 °C. Prior to luciferase expression analysis, plates were brought to RT for 1 h under constant gentle shaking conditions. For mRNA, the cell lysates were diluted 1:100 in PBS. A total of 35 µL of cell lysate was dispensed into an opaque 96-well plate for measurement. Luciferase activity was recorded for 10 s in a Centro LB 960 plate reader luminometer (Berthold Technologies, Bad Wildbad, Germany) after addition of 100 μL LAR buffer (20 mM glycylglycine; 1 mM MgCl2; 0.1 mM ethylenediaminetetraacetic acid; 3.3 mM dithiothreitol; 0.55 mM adenosine 5′-triphosphate; 0.27 mM coenzyme A, pH 8–8.5) supplemented with 5% (v/v) of a mixture of 10 mM luciferin and 29 mM glycylglycine. Transfection efficiency was calculated as relative light units (RLU) per well. For mRNA, a background (i.e., RLU values of HBG-treated cells) subtraction was performed.
2.2.8. Cellular Uptake Study-Flow Cytometry
At 24 h before the experiment, KB cells were seeded in a 24-well plate at a density of 50,000 cells/well. Transfection was then carried out by applying a volume of 6 µL of LAF polyplexes prepared at a mRNA concentration of 12 µg/mL (20% Cy5-labeled) as described (Section 2.2.3). After 2 h of incubation, the medium was removed, and cells were washed with 400 µL phosphate-buffered saline (PBS). Subsequently 400 µL of heparin was added (1000 IE/mL), and the plate was placed on ice for 10 min to remove polyplexes non-specifically bound to the cell surface. After incubation, heparin was removed, and the cells were again washed with PBS. Then, cells were detached using 100 µL trypsin/EDTA and diluted in 200 µL FACS buffer (PBS supplemented with 10% FBS), supplemented with 0.1% (v/v) DAPI (1 mg/mL) to stain the nuclei of dead cells. Cellular uptake was quantified using a CytoFLEX S flow cytometer (Beckman Coulter, Brea, CA, USA) with Cy5 excitation at 635 nm and emission detection at 665 nm. Cells were gated based on their forward- and sideward-scatter profiles. At least 14,000–20,000 events were recorded, and data was analyzed by FlowJo 7.6.5 flow cytometric analysis software (FlowJo, Ashland, OR, USA). The results are presented as the mean fluorescence intensity (MFI; n = 1) of all live cells.
2.2.9. Steric Stabilization of LAF-XP mRNA Polyplexes Against Salt-Induced Aggregation Through PEGylation
LAF-XP polyplex solutions (40 µL) were formed as described above () and diluted with 70 µL PBS. Subsequently, size was measured as described above (). Section 2.2.3 Section 2.2.4
2.2.10. pH-Triggered Deshielding and Destabilization of LAF-XP mRNA Polyplexes
LAF-XP polyplex solutions (20 µL) were formed as described above () at a concentration of 25 µg/mL. Subsequently, 180 µL of 0.01 mM HCl (pH 4) was added, and the samples were incubated for 30 min at 37 °C under constant shaking conditions (300 rpm). For control groups, 180 µL HBG (pH 7.4) was added, and the samples were incubated under identical conditions. Subsequently, samples were diluted with 700 µL PBS, and the size was measured as described above (). Section 2.2.3 Section 2.2.4
2.2.11. Steric Stabilization of LAF-XP mRNA Polyplexes Against Protein-Induced Aggregation Through PEGylation
Equal volumes of nucleic acid solution and LAF-XP carrier/PEG lipid solution were mixed by rapid pipetting and incubated for 40 min at RT in a closed Eppendorf reaction tube to give 25 µL of LAF-XP polyplex solution with a concentration of 25 μg/mL mRNA. Subsequently, 15 µL of human transferrin solution was added, resulting in a final mRNA concentration of 12.5 µg/mL, with the indicated molar ratios of human transferrin to carrier. After an incubation of 10 min, the PDI and zeta potential were measured as described above (). Section 2.2.4
2.2.12. Serum Assay–Preparation of Serum-Incubated LAF-XP mRNA Polyplexes
LAF-XP polyplexes were formed as described above (), using a concentration of 10 µg mRNA/150 µL. The polyplexes were incubated in 90% fetal bovine serum (FBS) for 2 h at 37 °C under continuous shaking conditions at 300 rpm. Section 2.2.3
2.2.13. DLS Measurements of Serum-Incubated LAF-XP mRNA Polyplexes
For DLS measurements, 40 µL of the FBS-incubated samples was mixed with 40 µL of HBG, yielding a final volume of 80 µL. The solution was transferred to a folded capillary cell. Size was analyzed with the settings described above (). Section 2.2.3
2.2.14. Nanoparticle Tracking Analysis of Serum-Incubated LAF-Xp mRNA Polyplexes
The particle concentration was determined at 25 °C using a NanoSight NS300 (Malvern Instruments, Malvern, UK) equipped with a blue 488 nm laser and sCMOS camera. The FBS-incubated samples (serum dilution 1:10) were diluted 1:200 with HEPES buffer (7.4), resulting in a total dilution of 1:2000. The diluted samples were injected via the integrated syringe pump at a speed of 20 AU following the manufacturer's instructions. Five runs per sample were conducted. Videos were recorded at a frame rate of 25 fps, with a total of 1498 frames analyzed per measurement. The detection threshold was set to 10. The maximum jump mode, blur, and minimum track length were operated in automatic mode.
2.2.15. Transfection Efficiency Assessment of Serum-Incubated LAF-XP mRNA Polyplexes
Next, 2.25 µL of the serum-incubated LAF polyplexes were added to the corresponding wells in triplicate. As a control, a portion of the original LAF polyplexes was diluted in HBG instead of serum prior to transfection and also added at a volume of 2.25 µL per well in triplicate.
2.2.16. Isolation and Purification of Protein-Corona-Coated LAF-XP mRNA Polyplexes
LAF-XP mRNA polyplexes were formed as described above (Section 2.2.3), using a concentration of 1 µg mRNA/50 µL. The polyplexes were then mixed with mouse serum at a 1:1 volume ratio and incubated for 15 min at 37 °C at 300 rpm. A 0.7 M sucrose solution was prepared by dissolving solid sucrose in Milli-Q H2O. The serum-incubated polyplexes (100 µL) were carefully pipetted onto a 300 µL cushion of 0.7 M sucrose and centrifuged at 15,300× g for 1 h at 4 °C. Following centrifugation, the supernatant was discarded. The resulting pellet was washed with 400 µL sterile PBS. The pellet was centrifuged again at 15,300× g for 5 min at 4 °C, and the supernatant was removed. This washing step was repeated two additional times for a total of three washes. All pipetting steps were performed using sterile filter tips. Subsequently, samples were stored at −20 °C until further analysis (MS analysis and SDS-PAGE).
2.2.17. Protein Corona Determination via Mass Spectrometry (MS) Analysis of Serum-Coated mRNA LAF-XP Polyplexes
Prior to mass spectrometry analysis, samples were prepared as follows: Evotip PURE tips were rinsed with Buffer B (comprising 80% ACN, water, and 0.1% formic acid) and spun down at 800× g for 60 s. The tips were then equilibrated in 20 µL of Buffer A (0.1% formic acid) and impulse spun at 800 g for storage until the acidified samples were ready to load. Samples were acidified in 0.4% TFA, and the Evotip PURE was emptied by centrifuging at 800× g for 1 min. The acidified samples were loaded onto the Evotip PURE tips and spun at 800× g for 1 min. The samples were washed twice with 20 µL of Buffer A and spun down at 800× g for 1 min. Elutions were collected in PCR strips by eluting with 20 µL of 45% Buffer B (containing 45% ACN, water, and 0.1% TFA) at 450× g. After drying in a SpeedVac and resuspended in 0.1% TFA supplemented with 0.015% DDM, samples were analyzed using liquid chromatography with tandem mass spectrometry (LC−MS/MS; EASY nanoLC 1200, Thermo Fisher Scientific) coupled with a trapped ion mobility spectrometry quadrupole time-of-flight single-cell proteomics mass spectrometer (timsTOF SCP; Bruker Daltonik) via a CaptiveSpray nano-electrospray ion source. A total of 50 ng of sample per injection was loaded on a 5.5 cm High Throughput μPAC Neo HPLC Column (Thermo Fisher Scientific) and analyzed using an 80 min active gradient method at a flow rate of 250 nl min−1. Data were analyzed using scanpy (v. 1.10.2) and anndata (v. 0.10.8) in Python 3.11. Thirty independent samples were analyzed from each group (n = 2). All proteins expressed in less than half of the samples in each group were filtered out, resulting in 684 proteins used for downstream analyses. The data was log-transformed and normalized per sample. The missing values were input using KNNImputer (n_neighbors = 5) from the sklearn package (v. 1.5.1). With scanpy's dendrogram function scipy's hierarchical linkage clustering was calculated on a Pearson correlation matrix over groups for 50 averaged principal components. Differential expression analysis was conducted using Scanpy's method "rank_genes_groups" with the method set to "t-test". A threshold of p < 0.05 and |log fold change| > 1.0 were applied to identify differentially expressed proteins (DEPs). These DEPs were subsequently visualized using volcano plots.
2.2.18. SDS-PAGE and Silver Staining of Protein-Corona-Coated mRNA LAF-XP Polyplexes
Samples were thawed on ice and 20 µL of Milli Q H2O, and 10 µL reducing loading buffer (30% glycerol (v/v); 0.7 mM Tris pH 6.8; 10% SDS (w/v); 0.12 mg/mL bromophenol blue; 0.93 mg/mL DTT; and 0.01% β-mercaptoethanol (v/v)) were added. Subsequently, the samples were shaken (300 rpm) at 95 °C for 5 min and applied onto a 3.5–10% gradient SDS gel according to the Laemmli method and separated at 30 mA for 120 min in a Mini-PROTEAN II electrophoresis cell (Bio-Rad, Hercules, CA, USA).
After electrophoresis, the gel was placed in a clean tray and washed three times for 5 min each with 50–100 mL pure H2O. The Imperial Protein Stain was gently mixed before use by inverting the bottle several times. Gels were stained for 2 h at room temperature, followed by destaining in ultrapure H2O for three days with several water changes until background staining was minimized. Quantification was performed using ImageJ, (version 1.54g). Percentage change (% change) was calculated by using the formula % change=100 ×1−Intensity 1752Intensity 1611 and % change=100×1−Intensity PEGylatedIntensity unmodified. Three protein bands were quantified at approximately 70, 15, and 8 kDa.
2.2.19. Statistical Analysis
The results are presented as mean values (arithmetic mean) of triplicates. Error bars display the standard deviation (SD). Statistical analysis of the results (mean ± SD) was evaluated by an unpaired t-test with Welch's correction; ns, not significant; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤0.0001.
3. Results and Discussion
For mRNA delivery, the current best-performing carriers, two U1 U-shape (1611 and 1719) and two B2 bundle LAF-XPs (1621 and 1752), were applied (Scheme 1b,c).
3.1. Formulation and Physicochemical and In Vitro Assessment of PEGylated LAF-XP mRNA Polyplexes
LAF-XP polyplexes were assembled in a 50:50 (v/v) solvent of HBG (HEPES-buffered glucose) and water [78]. To utilize the solvent advantages of LAF-XP polyplexes, DMG-PEG and DSPE-PEG-N3 stock solutions were also prepared in water. This enabled their use in the classic LAF-XP polyplex preparation protocol. A new, slightly modified preparation method was established. Nucleic acid was diluted in HBG. The PEG lipids were co-diluted with the LAF-XP carrier in water at indicated molar ratios of total lipids. Equal volumes of nucleic acid solution and the LAF-XP/PEG lipid solution were mixed by rapid pipetting and incubated for 40 min at RT in a closed Eppendorf reaction tube (Scheme 1f).
To assess the impact of the PEGylation, an in-depth physicochemical characterization, which included dynamic light scattering (DLS), a Ribogreen assay, and an agarose gel shift, was conducted. Subsequently, the PEGylated LAF-XP polyplexes were tested regarding their transfection efficiency and metabolic activity in N2A and KB cell lines. Each carrier was formulated at its respective optimal nitrogen-to-phosphate ratio (N/P) [71,78].
For B2 LAF-XP mRNA polyplexes, PEGylation had a particularly favorable effect on the Z-average. Both PEG lipids led to the formation of smaller particles, whereas for U-shapes, only DMG-PEG had a size-reducing effect. In terms of the PDI, no notable changes could be seen (Figure 1a). Regarding the zeta potential, PEGylation led to a reduction for all carriers, and no considerable differences were observed between DMG-PEG and DSPE-PEG-N3 in this regard (Figure 1b).
Previous studies have shown that PEGylation can interfere with nucleic acid compaction [79,80]. Therefore, a RiboGreen assay and a gel shift were conducted. The results indicated that PEGylation did not compromise encapsulation efficiency for the U-shapes 1611 and 1719. However, when incorporated into B2 bundles 1752 and 1621, a reduction in encapsulation, especially at higher molar ratios, could be seen (Figure 1c). These results were confirmed in an agarose gel shift assay. For bundles, PEGylation-induced smearing, particularly at higher molar ratios. For U-shapes, again no notable impact on compaction efficiency could be observed (Figure S3).
An increase in PEGylation universally resulted in a decline in transfection efficiency (Figure 2d and Figure S4a). These findings are consistent with the results obtained from DLS measurements, where the zeta potential was decreased by PEG. Previous work has shown that due to the reduced zeta potential, interactions with cellular and endosomal membranes are inhibited. Both cellular uptake and endosomal escape are hindered, which ultimately leads to a reduced transfection efficiency [81,82,83,84,85]. This may also explain why the transfection efficiency of U-shapes was more strongly affected by PEGylation compared to bundles. The decrease in zeta potential was substantially more prominent in U-shapes. In addition, other factors may contribute to the observed differences in behavior. For bundles, PEGylation reduced mRNA compaction, which can often lead to reduced transfection efficiency. However, excessive mRNA compaction can also hinder its release. In the case of bundles, PEGylation may simultaneously lower cellular uptake and endosomal escape while facilitating mRNA release in the cytoplasm. These opposing effects could partially counterbalance each other.
For all carriers, DSPE-PEG-N3 led to a stronger reduction in transfection efficiency than DMG-PEG (Figure 1d and Figure S4a).
DSPE-PEG-N3, featuring a longer lipid anchor (two C18 hydrocarbon chains), likely forms stronger lipophilic interactions with the LAF domain of the carriers. This results in more stable anchoring and long-lasting PEG shielding. In contrast, weaker anchoring of DMG-PEG, due to its shorter lipid anchor (two C14 hydrocarbon chains), allows dissociation from LAF-XP mRNA polyplexes, promoting cell interactions. This likely accounts for the higher transfection efficiency.
This makes DSPE-PEG-N3 suitable for incorporating targeting ligands. Its azido group enables functionalization with targeting moieties via copper-free azido/DBCO click chemistry.
Furthermore, an MTT assay revealed no substantial effect of PEGylation on metabolic activity (). Figure S4b,c
Finally, the anchoring mechanism of the PEG lipids under physiological and endosomal acidic conditions was evaluated (Figure S5). The size and zeta potential of unmodified and fully shielded (20% DSPE-PEG-N3) LAF-XP mRNA polyplexes were compared after an incubation at either pH 7.4 or at pH 5.4. As observed before, under physiological conditions the shielded particles exhibited a strongly reduced zeta potential. Upon acidification, however, the zeta potential experienced a sharp increase (9.4-fold for 1611, 3.8-fold for 1621), suggesting a loss in shielding. These findings support the hypothesis that the PEG lipids are released from polyplexes with endosomal protonation of the lipidic LAF domains (Scheme 2). For the unmodified formulations, the rise in zeta potential (1.4 for 1611 and 1.9 for 1621) was not as drastic as for the shielded ones.
3.2. Targeting of LAF-XP mRNA Polyplexes with GE11
Tumor-specific nucleic acid delivery still remains challenging [86]. The particles must be shielded, meaning they should exhibit a neutral zeta potential to prevent nonspecific cellular interactions. To ensure delivery to the intended site, a targeting moiety has to be incorporated. A promising approach involves the use of ligands, which have demonstrated high potential in various studies [32,87,88,89,90,91,92,93,94]. For instance, GE11 is a phage-derived peptide ligand and consists of 12 amino acids with the sequence H2N-YHWYGYTPQNVI-COOH, specifically targeting the epidermal growth factor receptor (EGFR). It has shown encouraging results both in vitro and in vivo [95,96,97,98,99]. In the following study (Scheme 2), the GE11 peptide was functionalized with an N-terminal DBCO moiety. This enables azido/DBCO copper-free click reactions to DSPE-PEG-N3, yielding a DSPE-PEG-2k-GE11 conjugate (DSPE-PEG-GE11). The identity and purity of the DBCO-GE11 peptide conjugate was confirmed by MALDI-TOF-MS and HPLC (Figure S1). For mRNA, DSPE-PEG-N3 at molar ratios of 10% and 20% exhibited a significantly decreased zeta potential and transfection efficiency for all carriers. These molar ratios are ideal for targeting. Consequently, 1611 was selected for targeting studies due to its superior mRNA compaction at high molar ratios of PEG. In accordance with the newly established formulation protocol, the DSPE-PEG 2 kDa-GE11 conjugate was used in the same manner as DSPE-PEG-N3 (Scheme 1f).
DLS measurements revealed that GE11-functionalized mRNA particles exhibited small, uniform sizes with a neutral zeta potential (Figure 2a).
Three EGFR-expressing cell lines HEPG2, HUH7, and KB were selected to assess the transfection efficiency of GE11-functionalized 1611 LAF-XP polyplexes. Unmodified, shielded (10% and 20% DSPE-PEG-N3), and targeted (10% and 20% DSPE-PEG-GE11) formulations were evaluated. Shielded 1611 exhibited lower transfection efficiency, which was restored by GE11 functionalization (Figure 2b).
In order to investigate the specificity of the ligand–receptor interaction, a constitutional isomer of GE11 (GE11-scr) was synthesized (Figure S2). This was first reported by Yu et al.; in their study, the original amino acid sequence (H2N-YHWYGYTPQNVI-COOH) was scrambled, resulting in a new sequence: H2N-YWGPNIHYYTQV-COOH [100]. In the same way as for the GE11 peptide, the GE11-scr peptide was functionalized with a DBCO group and conjugated with DSPE-PEG-N3.
GE11-scr-functionalized 1611 LAF-XP polyplexes formed smaller particles with a higher zeta potential compared to those functionalized with GE11 (Figure 2a,c). However, unlike GE11, the scrambled GE11 did not enhance transfection efficiency. No considerable differences were observed between shielded and GE11-scr-functionalized particles (Figure 2d). Subsequent uptake measurements supported these findings. Shielding reduced cellular uptake, while GE11-functionalized LAF-XP polyplexes recovered uptake nearly to the extent of unmodified LAF-XP polyplexes. In contrast, GE11-scr-functionalized LAF-XP polyplexes exhibited uptake levels similar to shielded particles (Figure 2e).
3.3. PEGylation and GE11 Targeting of LAF-XP pDNA Polyplexes
For analogue pDNA investigations, U1 U-shapes 1611 and 1719, as well as the B2 bundle 1730, were selected (Scheme 1b,c). Similar trends to those for mRNA were observed. DLS measurements revealed that the size and PDI remained largely unchanged upon PEGylation, whereas zeta potential was reduced (Figure S6a,b). Furthermore, an ethidium bromide (EtBr) assay showed no substantial impact of PEGylation on pDNA binding ability (Figure S6e). LAF–XP pDNA polyplexes are generally more stable than their mRNA counterparts. They tend to aggregate less during particle formation, can be prepared at lower N/P ratios, and compact pDNA better than mRNA. These features likely explain why PEGylation has little impact on pDNA compaction, whereas it can affect the compaction of mRNA polyplexes.
No considerable differences were detected between DMG-PEG and DSPE-PEG-N3 in the physicochemical evaluation. However, regarding transfection efficiency, DSPE-PEG-N3 led to a stronger reduction than DMG-PEG (). As observed with LAF-XP mRNA polyplexes, this can again be attributed to the differing anchor lengths of the two different PEG lipids. Figure S6c
For GE11 targeting, unmodified and shielded (25% DSPE-PEG-N3) 1719 was compared to targeted (25% DSPE-PEG-GE11) 1719. Shielding resulted in a lower transfection efficiency, confirming the results from the initial screening. GE11 functionalization led to the recovery of the transfection efficiency in HepG2 cells, and in HUH7 cells it even outperformed the unmodified formulation (). Figure S7b
3.4. Colloidal Stability
In vitro evaluation revealed that DMG-PEG at low molar ratios does not considerably reduce transfection efficiency. Previous work has shown that the addition of small amounts of PEG also improves the colloidal stability of cationic polymer delivery systems [35,101,102]. In subsequent experiments, we aim to improve colloidal stability with low amounts of DMG-PEG but not at the cost of reduced transfection efficiency.
3.4.1. Steric Stabilization of LAF-XP mRNA Polyplexes Against Salt-Induced Aggregation Through PEGylation
The ionic strength of the physiological environment can present a substantial risk to the stability of cationic delivery systems. Salts can interfere with the electrostatic interactions between the cationic carrier and the anionic nucleotide backbone, leading to aggregation [16,103]. PEG on the surface of polyplexes can provide protection against salt-induced aggregation through steric stabilization [32,104,105,106,107,108,109]. In a similar manner, we investigated whether PEGylation could sterically stabilize the LAF-XP polyplexes. We chose two molar ratios of DMG-PEG (3% and 10%) and compared them to unmodified carriers. After LAF-XP polyplex formation, an aliquot of phosphate-buffered saline (PBS) was added, and size was determined at different time points.
Interestingly, unmodified LAF-XP mRNA polyplexes exhibited topology-dependent differences in colloidal stability upon PBS addition. B2 bundles (1752 and 1621) aggregated immediately. U-shapes were more stable, with 1719 aggregating after 150 min and 1611 only after 18 h (Figure 3). The difference in stability is likely due to the different structural and cationic properties of B2 bundles and U-shapes. The B2 bundles are more hydrophobic and less cationic due to a higher content of LAF residues that are not protonated at physiological pH. In contrast, U-shapes have a lower LAF content and include an additional primary amine in their backbone. This presumably enables stronger electrostatic interactions and compaction of mRNA. A stronger binding in U-shapes is consistent with delayed salt-induced aggregation. PEGylation with both 3% and 10% DMG-PEG prevented aggregation completely in bundles and U-shapes, even after 24 h (Figure 3). Especially, the B2 bundles, with weaker binding, therefore benefit more from PEGylation.
The strong increase in zeta potential under endosomal conditions as observed in Section 3.1 suggests that protonation of the LAF carriers leads to dissociation of the PEG lipids from the polyplexes. Consequently, a functional loss of stability would also be predicted in the presence of salt. To verify this, a second PBS stability study was conducted with 1621 polyplexes (Figure S8). Unmodified and PEGylated polyplexes (0.5% and 1% DMG-PEG) were incubated under acidic conditions before PBS was added for incubation in salt at neutral pH. As a control, standard PEGylated polyplexes (without acidic preincubation) were incubated at pH 7.4. Consistent with the previous findings, unmodified 1621 LAF-XP mRNA polyplexes were immediately aggregated with PBS, whereas PEGylated polyplexes remained stable upon incubation with PBS at pH 7.4. In contrast, PEGylated polyplexes pre-exposed to acidic conditions exhibited aggregation in PBS pH 7.4. The deshielded PEGylated polyplexes aggregated at a markedly slower rate than their unmodified counterpart (Figure S9). This suggests that PEG lipids are only partially released under acidic conditions. Nevertheless, this partial deshielding is apparently sufficient for restored high transfection efficiency (Scheme 2 and Figure 2).
3.4.2. Reduction in the N/P Ratio Through PEGylation
Bundles 1621 and 1752 require a higher N/P ratio (N/P 24) to form small and stable particles. At lower N/P ratios, these carriers tend to aggregate, especially at higher concentrations. We investigated whether the bundles 1621 and 1752 could be formulated at half of the standard N/P ratio (N/P 12 instead of N/P 24) by incorporation of low molar amounts of DMG-PEG (1.5% and 3%) at in vivo concentration 33.3 µg/mL (5 µg mRNA in 150 µL).
As expected, unmodified 1752 and 1621 aggregated at N/P 12. The incorporation of low molar amounts of DMG-PEG led to the formation of small and stable particles with low PDIs and successfully prevented aggregation (). Figure S9
3.4.3. Overcoming mRNA LAF-XP mRNA Polyplex Instability Through PEGylation
Encouraged by the successful reduction in the N/P ratio in 1752 and 1621, we hypothesized that the PEGylation strategy can be applied to carriers that previously could not be formulated. Thalmayr et al. reported that carriers 1716 and 1613 failed to form stable particles due to severe aggregation [71]. Structurally, 1716 and 1613 are highly similar. Both contain 12Oc as their LAF unit and have nearly identical molecular weights. They only differ in their topology. Carrier 1613 is a B2 bundle, while 1716 is a U4 U-shape. The combination of four LAF 12Oc motifs with a single Stp unit appears to result in highly unstable structures. However, both carriers were successfully formulated as LNPs, with 1716 demonstrating a particularly high transfection efficiency [74]. The carriers were PEGylated (1.5% and 3% DMG-PEG) at the N/P ratios of 12 and 18 (Figure 4a). At N/P 12, both unmodified carriers underwent aggregation. However, PEGylation significantly improved size and uniformity. It was found that 1.5% DMG-PEG successfully prevented aggregation, although it resulted in larger particles. Nevertheless, the formulations exhibited good uniformity with favorable PDIs. In addition, 3% DMG-PEG facilitated optimal particle formation for both 1613 and 1716. Notably, these formulations exhibited very low zeta potential, approaching near-neutral values. At N/P 18, both 1.5% and 3% DMG-PEG modification resulted in the formation of small particles with a low PDI and positive zeta potential.
Subsequently, the different formulations were tested regarding their transfection efficiency in N2a and KB cells. They were compared to 1611 and 1719, which represent the current gold standard for mRNA transfection within the U-shape class. Carrier 1716 with 1.5% DMG-PEG outperformed both unmodified 1611 and 1719 in transfection. In contrast, unmodified 1716 aggregates exhibited poor transfection efficiency, emphasizing the positive impact of PEGylation. Carrier 1613 demonstrated limited transfection efficiency compared to the other carriers. Here, PEGylation only had a positive effect on transfection efficiency in KB cells, where a slight increase in transfection efficiency was observed (Figure 4b).
Our previous work demonstrated that 1719 had a lower transfection efficiency in vivo compared to 1611, 1621, and 1752 [71]. Therefore, the focus in subsequent experiments was placed on these three in vivo best-performing carriers.
3.5. Protein Corona
In vitro transfection activity often does not match in vivo activity [110,111,112]. Upon exposure of nanoparticles to biological fluids, a protein corona forms on the surface that strongly influences further distribution and biological efficacy [113,114,115,116,117,118,119,120,121,122,123,124,125]. The novel LAF-XP mRNA polyplexes exhibit unexpectedly high transfection efficiency in the presence of full serum even at a very low dose [71,72]. This is in sharp contrast to classic cationic polymer delivery systems, where serum typically impairs the transfection efficiency [126]. The zwitterionic nature of the LAF-XP carriers at physiological pH suggests that they exhibit a different protein corona compared to purely polycationic delivery systems. In the case of LPEI, plasma proteins such as IgM, fibrinogen, fibronectin, and complement C3 were found to bind to non-PEGylated polyplexes [32]; furthermore it has been demonstrated that PEG shielding significantly reduces protein adsorption and improves in vivo performance of DNA polyplexes. To assess the effect of PEGylation on the protein corona composition of mRNA LAF-XP polyplexes, unmodified and PEGylated 1611 and 1752 (10% DSPE-PEG-N3) were incubated in serum, and unbound proteins were removed via centrifugation. Finally, SDS-PAGE with subsequent Coomassie staining was performed (imperial protein stain) (Figure S10a).
The 1611 and 1752 polyplexes exhibited distinct differences in protein adsorption. Unmodified 1611 showed higher protein adsorption compared to unmodified 1752. For both carriers, PEGylation with 10% DSPE-PEG-N3 visibly reduced protein adsorption. To quantify these differences, the intensities of the three most prominent protein bands (~70 kDa, 15 kDa, and 8 kDa) were analyzed using ImageJ. Quantitative analysis revealed that unmodified 1752 adsorbed less protein than 1611 across all bands. This difference likely derives from their distinct chemical composition. Carrier 1752, rich in LAF motifs, is less cationic, whereas 1611 has fewer LAF moieties and more resembles classical cationic delivery systems such as LPEI. The reduced protein adsorption of the 1752 LAF-XP mRNA polyplexes suggests that the LAF motif exerts a shielding effect. PEGylation further reduced protein adsorption in both carriers (). Figure S10b
Subsequently, the protein coronas of 1611 and 1752 mRNA polyplexes without or with PEGylation (3% DMG-PEG) were investigated in more detail using proteomic methods. This methodological approach allowed the detection of differences in the composition of the protein corona, whereas quantitative changes in the total amount of protein cannot be resolved.
Initial analysis of the unmodified carrier polyplexes suggests that fibrinogen (Fgg) was upregulated in 1611 compared to 1752 (Figure 5a). Fibrinogen is a large, negatively charged glycoprotein. It is known to bind strongly to positively charged particles. Carrier 1611 exhibits a zeta potential of 25–35 mV, whereas 1752 shows a markedly lower zeta potential of approximately 10 (Figure 1a). Upon PEGylation with 3% DMG-PEG, the zeta potential of 1611 is decreased to ~13. PEGylated 1611 polyplexes thus show a zeta potential comparable to unmodified 1752 polyplexes (Figure 1a). As a result, PEGylated 1611 nanoparticles exhibit significantly reduced fibrinogen adsorption (Figure 5b,d). In contrast, 1752 polyplexes inherently adsorb less fibrinogen. Here PEGylation did not further decrease fibrinogen adsorption (Figure 5c,d). This difference is likely attributed to the distinct structural composition of the carriers. Carrier 1752 contains an Stp/LAF ratio of 1:4, whereas 1611 has a ratio of 1:2. The higher Stp content in 1611 likely contributes to its higher zeta potential. The cationic polar Stp unit is a structural derivative of LPEI, which is also known to strongly adsorb fibrinogen. PEGylation of highly cationic LPEI polyplexes likewise resulted in less fibrinogen adsorption [32]. In contrast, the amphiphilic LAF domain behaves differently. It is largely neutral and hydrophobic at physiological pH. In 1752, it likely accounts for its reduced zeta potential by partially neutralizing its surface charge. The decrease in fibrinogen adsorption implies that the LAF motif may provide a shielding effect.
3.6. Steric Stabilization of LAF-XP mRNA Polyplexes Against Protein- and Serum-Induced Aggregation Through PEGylation
Extensive research especially on cationic carrier systems has shown aggregation after intravenous application, resulting in toxicity [127]. Moreover, organ-specific targeting can be hampered. For instance, LPEI/DNA polyplexes at high doses aggregate with blood components, which passively accumulate in the lung, predominantly leading to high transfection of pulmonary tissue. This also poses a serious threat to biosafety. In the case of PEI, conjugation with PEG evaded these problems [24,32,128].
Initially, the stability of unmodified polyplexes with carriers 1611, 1752, and 1621 was investigated in the presence of negatively charged human transferrin (). Unmodified LAF-XP polyplexes were formulated according to the standard preparation protocol, followed by the addition of varying molar amounts of human transferrin (molar equivalent refers to the molar ratio of human transferrin to the carrier). Interestingly, contrary to the PBS results, 1611 appeared to be less stable than the bundles. It failed to form stable particles at any molar ratio of human transferrin. Carriers 1621 and 1752 formed stable particles at a molar equivalent of 0.25. As all carriers underwent aggregation at a molar ratio of 0.1 eq hTF, this ratio was chosen to investigate the impact of PEGylation. Figure S11a
The results were consistent with all carriers. PEGylation effectively prevented aggregation. Particles were slightly larger at 1.5% DMG-PEG compared to 3% DMG-PEG (). Minimal PEGylation again showed a great improvement in colloidal stability. Figure S11b
After intravenous application, besides ionic stress and protein adsorption, higher body temperature and shear forces may challenge the stability of the carriers even further [113,129,130,131]. Therefore, a serum assay was conducted. Here, LAF-XP polyplexes were tested in the presence of electrolytes, proteins, higher temperature, and shear forces all at once. Unmodified and PEGylated (3% and 10% DSPE-PEG-N3/DMG-PEG) LAF-XP mRNA polyplexes, formulated at in vivo concentration (10 µg/150 µL), were incubated in 90% fetal bovine serum for 2 h under continuous shaking conditions at 300 rpm at 37 °C. Subsequently, serum-incubated LAF-XP polyplexes were tested regarding their size and transfection efficiency.
The first DLS measurements were conducted. Prior to measurement, serum-incubated polyplexes were further diluted with HBG, resulting in a final serum concentration of 45%. Subsequently DLS measurements were performed. Unmodified carriers showed aggregation after 2 h (). Especially, the bundles 1621 and 1752 benefited from PEGylation. Both PEG lipids, DMG-PEG and DSPE-PEG-N3, at molar ratios of 3% and 10%, effectively prevented aggregation. Interestingly, as in the stability study with human transferrin, 1611 polyplexes appeared to be less stable. In that case, DMG-PEG at any molar ratio failed to improve stability. Only DSPE-PEG-N3 prevented aggregation (). Figure S12b Figure S12b
DLS measurements have limitations in polydisperse samples. Large aggregates might mask smaller particles, leading to underrepresentation of the smaller particle populations. Therefore, to further support these findings, nanoparticle tracking analysis (NTA) was performed. In order to distinguish the serum background from LAF-XP polyplexes, a serum blank was measured prior to the polyplex measurements (Figure 6a). The observed trends were very similar to the DLS results. The unmodified carriers exhibited aggregation after 2 h. They formed large, bright particles that prevented precise NTA quantification (Figure 6b). For 1621, PEGylation greatly improved colloidal stability, with 3% DMG-PEG effectively preventing aggregation. Both PEG lipids, DMG-PEG and DSPE-PEG, enhanced particle stability (Figure 6b and Figure S13a). The 1611 polyplexes again appeared to be less stable. For DMG-PEG, particle stabilization was achieved only at a molar ratio of 10%, whereas 3% was insufficient (Figure S13b). In contrast, for DSPE-PEG-N3, 3% improved stability and prevented aggregation (Figure 6b).
These results indicate that bundle carriers 1621 and 1752 benefit from PEGylation to a greater extent than the U-shape 1611. This is likely due to their higher number in apolar LAF domains (1621 and 1752 B2 bundles—4 LAF domains, 1611 U-shape—2 LAF domains), in which the PEG lipids may be better anchored. This would also explain the superior stabilizing effect of DSPE-PEG-N3 compared to DMG-PEG in 1611 LAF-XP polyplexes.
Furthermore, transfection efficiency upon serum incubation was assessed. As a control, LAF-XP polyplexes were diluted in HBG instead of serum prior to transfection (Figure 6c). The DSL measurement has shown that 3% PEG resulted in stabilization. Therefore, only LAF-XP polyplexes, PEGylated at a molar ratio of 3% PEG-DSPE/DMG, were examined.
The luciferase expression assay revealed that the unmodified carriers were not negatively affected by serum incubation. In fact, for the bundles 1621 and 1752, serum incubation even enhanced transfection efficiency compared to their HBG diluted counterparts. On the other hand, the transfection efficiency of 1611 remained largely unchanged.
For bundle carriers 1621 and 1752, PEGylation under serum-free conditions resulted in a decrease in transfection efficiency with DSPE-PEG-N3 again having a stronger effect. In the presence of serum, however, this reduction in transfection efficiency was less pronounced. In fact, for 1621, 3% DMG-PEG enhanced the transfection efficiency.
Similarly, for 1611 under serum-free conditions, PEGylation led to a decrease in transfection efficiency. However, in the presence of serum, the trends were the opposite. PEGylation led to an increase in transfection efficiency. DSPE-PEG-N3 (containing a larger lipid anchor) outperformed DMG-PEG. This reversed trend might be explained by the prior DLS measurement, which revealed that DSPE-PEG-N3 at 3% managed to better stabilize the particles, which ultimately leads to enhanced transfection efficiency. Besides the different Stp/LAF ratio, the topology may also have a large impact on PEG anchoring. In the bundles, the LAF domains are forced to stay in close proximity as they are connected via lysine residues. In contrast, in 1611 the two LAF moieties are separated by the Stp unit. Bundles may more easily form more localized lipophilic regions in which PEG lipids are more stably anchored. Moreover, 1611 contains a primary amine in its backbone, which might interfere with lipophilic interactions between the LAF unit and the lipid anchors.
3.7. In Vivo Dose Study: 1621 and 1752
Carriers 1621 and 1752 greatly benefit from PEGylation and were therefore selected for intravenous application. A dose escalation study was conducted to evaluate whether minimal PEGylation (3% DMG-PEG) would allow the injection of a higher mRNA dose. Specifically, for 1621, a starting dose of 5 µg mRNA was selected (A/J mice), and for 1752, the starting dose was 6 µg mRNA (N2a tumor-bearing NMRI mice).
Upon injection of the high dose of unmodified 1621 and 1752 LAF-XP mRNA polyplexes, mice suffered from severe toxicity symptoms and had to be euthanized. The dose had to be reduced for the remaining animals and was then well tolerated. In contrast, the higher doses were tolerated with the PEGylated formulations, which exhibited no signs of toxicity.
These observations indicate that PEGylation may contribute to biosafety as its ability to prevent aggregation, thus improving stability, made it possible to increase the dose. Regarding transfection efficiency, there were no notable differences between the unmodified and the PEGylated formulations (). Figure S14a,b
To explore any effect of PEGylation on tumor accumulation, polyplexes of unmodified 1621 (at the low dose of 2.5 µg mRNA) and PEGylated 1621 (at the low and high doses of 2.5 µg and 5 µg mRNA) were intravenously injected into N2a tumor bearing A/J mice. The higher dose of 5 µg mRNA of the PEGylated formulation was again well tolerated, confirming the results from the initial dosing study (). A comparison between the PEGylated and the unmodified formulation did not show notable differences in tumor expression signal or in other organs. These findings suggest that minimal PEGylation without targeting does not influence transfection efficiency but enhances biocompatibility. Figure S15
4. Conclusions
Several studies have shown that modification of cationic nanoparticles with hydrophilic polymers such as PEG improves colloidal stability, reduces nonspecific interactions with plasma proteins, and also decreases toxicity in vivo. However, such shielding may inactivate nanosystems as PEG may also impair binding to the target cell surface and endosomal membrane, decreasing the transfection efficiency. As a compromise, often only a suboptimum percentage (around 2 molar %) of PEG shielding agent has been applied. Several strategies have been developed to address this so-called PEG dilemma [83,84,132]. Targeting ligands have been successfully introduced to reestablish target cell surface interaction and endocytosis. This, however, does not necessarily restore the lipid membrane interaction required of endosomal destabilization and release into the cytosol [83]. Endosomal cleavage of PEG from nanoparticles via acid-labile [133,134,135,136], reducible [137], or enzymatically cleavable [138] linkers was found to restore endosomal escape and efficacy. In this study we present an alternative reversible shielding strategy to evade the drawbacks of conventional PEGylation. DSPE-PEG-N3 and DMG-PEG are anchored within the LAF-XP polyplex via hydrophobic interactions between the lipid tail of PEG lipids and the hydrophobic LAF domain of the carrier. However, in contrast to standard LNPs or lipoplexes, upon endosomal protonation of the LAF tertiary amine, the lipidic character of the LAF domain switches to a polar state [71]. As a result, hydrophobic anchoring of the PEG lipids is reduced, and the PEG lipids are assumed to dissociate from the polyplex surface under endosomal conditions.
Compared with LNPs, PEGylated LAF-XP polyplexes can be formulated in a simplified manufacturing process, with PEG lipids co-diluted with the LAF-XP carrier at neutral pH in water and subsequently flash-mixing with nucleic acids. No additional dilution or dialysis steps are required. PEGylation had a clear impact on physicochemical properties, decreasing the zeta potential. At high molar ratios (10% and 20%) of DSPE-PEG-N3, effective surface shielding was achieved. The EGFR-binding peptide GE11 was conjugated via copper-free click chemistry between its DBCO group and the azido group on DSPE-PEG-N3. GE11-functionalized LAF-XP polyplexes efficiently restored transfection efficiency in EGFR-positive cell lines. This platform demonstrates high flexibility and can be extended to other ligands or targeting moieties. Furthermore, a reduction in zeta potential was particularly beneficial for the more positively charged carrier 1611, resulting in decreased fibrinogen binding. LAF-rich 1752, exhibiting a low zeta potential, inherently showed low fibrinogen binding. PEGylation did not further reduce adsorption.
Low molar ratios of DMG-PEG (1.5% and 3%) were suitable for improving colloidal stability. Highly effective lipophilic LAF-XP carriers, previously stable only in LNP formulations, were able to form well-defined particles upon inclusion of 1.5% DMG-PEG. Furthermore, 3% DMG-PEG effectively prevented aggregation in the presence of salts, proteins, and full serum, improving biosafety of LAF-XP mRNA polyplexes. These findings represent an important step toward targeted nucleic acid therapies.